Hyponatraemia and vasopressin in heart failure: markers or mediators?

被引：10
作者：
Konstam, Marvin A. [1 ]
Udelson, James E.
机构：
[1] Tufts Med Ctr, CardioVasc Ctr, Boston, MA 02111 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2011年 / 13卷 / 03期
关键词：
PLASMA ARGININE VASOPRESSIN; SYSTOLIC DYSFUNCTION; CONTROLLED-TRIAL; ORAL TOLVAPTAN; DOUBLE-BLIND; ANTAGONIST; MULTICENTER; NONPEPTIDE; SODIUM;
D O I：
10.1093/eurjhf/hfq236
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：242 / 244
页数：3
相关论文
共 20 条
  • [1] Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
    Abraham, WT
    Shamshirsaz, AA
    McFann, K
    Oren, RM
    Schrier, RW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1615 - 1621
  • [2] Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study
    Aronson, Doron
    Verbalis, Joseph G.
    Mueller, Matthias
    Krum, Henry
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (03) : 327 - 336
  • [3] Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
    Costello-Boerrigter, LC
    Smith, WB
    Boerrigter, G
    Ouyang, J
    Zimmer, CA
    Orlandi, C
    Burnett, JC
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (02) : F273 - F278
  • [4] Non-peptide arginine-vasopressin antagonists: the vaptans
    Decaux, Guy
    Soupart, Alain
    Vassart, Gilbert
    [J]. LANCET, 2008, 371 (9624) : 1624 - 1632
  • [5] COMPARISON OF NEUROENDOCRINE ACTIVATION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION WITH AND WITHOUT CONGESTIVE-HEART-FAILURE - A SUBSTUDY OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD)
    FRANCIS, GS
    BENEDICT, C
    JOHNSTONE, DE
    KIRLIN, PC
    NICKLAS, J
    LIANG, CS
    KUBO, SH
    RUDINTORETSKY, E
    YUSUF, S
    [J]. CIRCULATION, 1990, 82 (05) : 1724 - 1729
  • [6] Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
    Gheorghiade, M
    Gattis, WA
    O'Connor, CM
    Adams, KF
    Elkayam, U
    Barbagelata, A
    Ghali, JK
    Benza, RL
    McGrew, FA
    Klapholz, M
    Ouyang, J
    Orlandi, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16): : 1963 - 1971
  • [7] Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure -: Results from a double-blind, randomized trial
    Gheorghiade, M
    Niazi, I
    Ouyang, J
    Czerwiec, F
    Kambayashi, J
    Zampino, M
    Orlandi, C
    [J]. CIRCULATION, 2003, 107 (21) : 2690 - 2696
  • [8] Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
    Gheorghiade, Mihai
    Abraham, William T.
    Albert, Nancy M.
    Stough, Wendy Gattis
    Greenberg, Barry H.
    O'Connor, Christopher M.
    She, Lilin
    Yancy, Clyde W.
    Young, James
    Fonarow, Gregg C.
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 (08) : 980 - 988
  • [9] Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
    Gheorghiade, Mihai
    Konstam, Marvin A.
    Burnett, John C., Jr.
    Grinfeld, Liliana
    Maggioni, Aldo P.
    Swedberg, Karl
    Udelson, James E.
    Zannad, Faiez
    Cook, Thomas
    Ouyang, John
    Zimmer, Christopher
    Orlandi, Cesare
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12): : 1332 - 1343
  • [10] INCREASED PLASMA ARGININE VASOPRESSIN LEVELS IN PATIENTS WITH CONGESTIVE HEART-FAILURE
    GOLDSMITH, SR
    FRANCIS, GS
    COWLEY, AW
    LEVINE, TB
    COHN, JN
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1983, 1 (06) : 1385 - 1390
12